Q. Isn’t there a risk that this will accelerate the adoption of drugs that aren’t ready and aren’t safe yet?

This isn’t a trade-off between speed and safety. This is about getting medicines designed specifically for patients who express biological characteristics (biomarkers) that increase the odds that a treatment will actually work for them. FDA is streamlining approvals for these treatments and personalized medicine can arguably have better safety and efficacy profiles than one-size fits all medicine of today.